

VÉTOQUINOL COMPLETES THE ACQUISITION OF WOCKHARDT ANIMAL HEALTH IN INDIA

August 20, 2009 (Lure, France) – Vétoquinol today announced the completion of its acquisition of the animal health business division of Wockhardt Limited, based in Mumbaï, India. This acquisition was the subject of an agreement signed with the Wockhardt Limited group on June 26.

With this acquisition, Vétoquinol becomes the sixth largest animal health company in India.

The prospects opened up by this acquisition will be discussed when Vétoquinol publishes its interim revenues report, on September 1.

About Vétoquinol

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group specialized exclusively in animal health is the 11th largest laboratory in the world, and more than 80% of Vétoquinol's revenues come from outside France. Vétoquinol engages in the research and development, production and marketing of medical and nutraceutical products. Vétoquinol has positioned itself in the curative sector, and has developed expertise in three therapeutic fields: anti-infectives, pain management and anti-inflammatories, and cardiology and nephrology.

The Group currently distributes its products in one hundred countries throughout Europe, North America and Asia, with subsidiaries in 23 different countries and a network of 140 distributor partners. The Company has more than 1,550 employees worldwide.

More information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For further information, contact:

VETOQUINOL

Finance Department
Pierre KONAREFF
Tel: +33 (0)3 84 62 59 88
relations.investisseurs@vetoguinol.com

KEIMA COMMUNICATION

Investor Relations
Emmanuel DOVERGNE
Tel: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr

Media Relations
Alix HERIARD DUBREUIL
Tel: +33 (0)1 56 43 44 62
alix.heriard@keima.fr